Technology company Echo IQ (ASX:EIQ) started the integration of its EchoSolv-AS decision support software with Beth Israel Deaconess Medical Center in the US, according to a Monday filing with the Australian bourse.
EchoSolv-AS is used to assess severe aortic stenosis, a condition where the heart's aortic valve is narrowed or blocked, causing blood to have difficulty passing through.
The integration follows a trial of EchoSolv-AS by Beth Israel researchers on a group of 31,000 patients, according to the filing.
Echo IQ shares rose past 11% in afternoon trade Monday.
Price (AUD): $0.25, Change: $+0.03, Percent Change: +11.11%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。